Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The key elements of our strategy to achieve this goal include executing on our INOpulse programs which we are evaluating for the treatment of pulmonary arterial hypertension (PAH),  pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with interstitial lung disease (PH-ILD).